Damora Therapeutics News and Activities

Damora Therapeutics is a company listed under the stock ticker DMRA (DK).

Acquisition, funding and merger involving Damora Therapeutics.

• Galecto Biotech will change its company name to Damora Therapeutics on Mar 10, 2026. (posted on March 10 2026).
• Damora Therapeutics has filed its IPO. Its stock ticker will be DMRA. (posted on March 9 2026).
• Damora Therapeutics is now listed under ticker DMRA. (posted on March 9 2026).

View the org chart displaying its 13 main executives

Most searched biographies at Damora Therapeutics

• Jennifer Jarrett, President and Chief Executive Officer
• Julianne Bruno, Director
• Mike Landsittel, Director

Popular executive movements at Damora Therapeutics

• Cameron Turtle has joined the company as Director  (posted on March 24 2026).
• Amit Munshi, Director, has left the company  (posted on March 24 2026).
• Mike Landsittel has joined the company as Director  (posted on March 24 2026).

Click here to view some more movements at Damora Therapeutics

Create your alert
to follow the executive moves at Damora Therapeutics.

Damora Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Damora Therapeutics

• Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Damora
• Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Damora
• Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Damora
• Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Damora
• News Releases | Damora
• News Releases | Damora
• Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Damora
• Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | Damora
• Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Damora
• Galecto Reports Second Quarter Operating and Financial Results | Galecto
• View more press releases Close

Social media about Damora Therapeutics

• Damora Therapeutics on Wikipedia, Google News & Yahoo Finance
• Damora Therapeutics on LinkedIn, X (Twitter) & YouTube